3 years after IPO, Anthera Pharma fights Nasdaq removal – San Francisco Business Times (blog)
|
3 years after IPO, Anthera Pharma fights Nasdaq removal
San Francisco Business Times (blog) NASDAQ in December notified Anthera, which has focused its drug-development work on a recently launched Phase III trial of the lupus treatment blisibimod, that the bid price of its stock had closed at less than $ 1 per share over 30 consecutive business … Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice |
